1-(2-溴乙基)-3,5-双(三氟甲基)苯 | 93427-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-溴乙基)-3,5-双(三氟甲基)苯
• 英文名称: 1-(2-bromo-ethyl)-3,5-bis-trifluoromethyl-benzene
• 英文别名: 1-(2-Bromoethyl)-3,5-bis(trifluoromethyl)benzene
• CAS: 93427-29-3
• 化学式: C₁₀H₇BrF₆
• 分子量: 321.06
• InChiKey: QQEAGUOAOUVLNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(2-溴乙基)-3,5-双(三氟甲基)苯 在 偶氮二异丁腈 、 三正丁基氢锡 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 21.0h， 生成 (+)-octahydro-3,6α-dimethyl-3,12-epoxy-9β-(3'-(3,5-bistrifluoromethylphenyl)propyl)-12H-pyrano[4,3j]-1,2-benzodioxepin-10(3H)-one
  参考文献：
  名称：

  Structure−Activity Relationships of the Antimalarial Agent Artemisinin. 8. Design, Synthesis, and CoMFA Studies toward the Development of Artemisinin-Based Drugs against Leishmaniasis and Malaria

  摘要：

  Artemisinin (1) and its analogues have been well studied for their antimalarial activity. Here we present the antimalarial activity of some novel C-9-modified artemisinin analogues synthesized using artemisitene as the key intermediate. Further, antileishmanial activity of more than 70 artemisinin derivatives against Leishmania donovani promastigotes is described for the first time. A comprehensive structure-activity relationship study using CoMFA is discussed. These analogues exhibited leishmanicidal activity in micromolar concentrations, and the overall activity profile appears to be similar to that against malaria. Substitution at the C-9beta position was shown to improve the activity in both cases. The 10-deoxo derivatives showed better activity compared to the corresponding lactones. In general, compounds with C-9alpha substitution exhibited lower antimalarial as well as antileishmanial activities compared to the corresponding C-9beta analogues. The importance of the peroxide group for the observed activity of these analogues against leishmania was evident from the fact that 1-deoxyartemisinin analogues did not exhibit antileishmanial activity. The study suggests the possibility of developing artemisinin analogues as potential drug candidates against both malaria and leishmaniasis.

  DOI：

  10.1021/jm030181q

文献信息

• [EN] ARTEMISININ-BASED PEROXIDE COMPOUNDS AS BROAD SPECTRUM ANTI-INFECTIVE AGENTS<br/>[FR] COMPOSES DE PEROXYDE A BASE D'ARTEMISININE TENANT LIEU D'AGENTS ANTI-INFECTIEUX A LARGE SPECTRE
  申请人：UNIV MISSISSIPI

  公开号：WO2003095444A1

  公开（公告）日：2003-11-20

  Described herein is the synthesis, bioassay results and utility of new C-9 and C-10 substituted artemisinin derivatives with easily functionalizable groups attached to the artemisinin skeleton through carbon chain or heteroatoms. Described also is the demonstration of this class of compounds for their broad-spectrum anti-parasitic activity. Certain of these analogs possess noticeable cytotoxicity deliberately focused on treatment of cancerous diseases.

  本文描述了合成、生物测定结果以及新的C-9和C-10取代青蒿素衍生物的用途，这些衍生物具有易于功能化的基团，通过碳链或杂原子连接到青蒿素骨架上。同时还展示了这类化合物在广谱抗寄生虫活性方面的表现。其中一些类似物具有明显的细胞毒性，专门用于治疗癌症性疾病。
• THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER
  申请人：Bajji C. Ashok

  公开号：US20070299258A1

  公开（公告）日：2007-12-27

  The invention relates to compounds of Formulae I-III and their therapeutic uses.

  这项发明涉及到I-III式化合物及其治疗用途。
• [EN] CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DE LA CYCLOPENTYLE-TACHYKININE
  申请人：MERCK & CO., INC.

  公开号：WO1997014671A1

  公开（公告）日：1997-04-24

  (EN) The present invention is directed to certain novel compounds represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein R3, R6, R7, R8, R11, R12, R13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulation in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.(FR) L'invention concerne de nouveaux composés représentés par la formule développée (I) ou leurs sels pharmaceutiquement acceptables. Dans ladite formule, R3, R6, R7, R8, R11, R12, R13, A, Q, W, X, Y, Z et n correspondent à la définition donnée dans la description. L'invention concerne également des formulations pharmaceutiques comportant comme ingrédients actifs ces composés, ainsi que l'utilisation de ces composés et de leurs formulations dans le traitement de certains troubles. Les composés selon l'invention sont des antagonistes des récepteurs des tachykinines et sont utiles dans le traitement des maladies inflammatoires, des douleurs et des migraines, de l'asthme et des vomissements.

  该发明涉及一些新的化合物，其结构式为(I)或其药学上可接受的盐，其中R3、R6、R7、R8、R11、R12、R13、A、Q、W、X、Y、Z和n在此定义。该发明还涉及包含这些新化合物作为活性成分的药物制剂以及在治疗某些疾病中使用这些新化合物和它们的制剂。该发明的化合物是缩短肽受体拮抗剂，可用于治疗炎症性疾病、疼痛或偏头痛、哮喘和恶心。
• NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME
  申请人：OHGIYA Tadaaki

  公开号：US20100249148A1

  公开（公告）日：2010-09-30

  A compound represented by the following general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R 6 represents an alkyl group, a cycloalkyl group and the like, R 7 and R 8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R 9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R 10 and R 11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

  以下是一种由通式（I）表示的化合物，其中R1、R2、R3、R4和R5表示氢原子、卤素原子、低碳基等，R6表示烷基、环烷基等，R7和R8表示氢原子、低碳基、（低环烷基）（低碳基）等，R9表示氢原子、卤素原子、低烷氧基等，R10和R11表示氢原子、低碳基、低烷氧基、卤基（低碳基）等，A表示由6到10个原子构成的杂环环，具有对胆固醇酯转移蛋白（CETP）具有强大的抑制活性。
• Therapeutic compounds and their use in cancer
  申请人：Myriad Pharmaceuticals, Inc.

  公开号：US07595401B2

  公开（公告）日：2009-09-29

  The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

  本发明涉及I式化合物及其治疗用途，其中取代基A选择自取代或未取代的芳基、杂芳基、杂环基或羧基，取代基B选择自取代或未取代的哌啶基、同哌啶基、吡咯烷基或氮杂环基，R1选择自氢、烷基、芳基、杂芳基氨基和卤素，L1和L2如说明书所定义。